Iron Triangle Partners LP Makes New Investment in Eli Lilly and Company $LLY

Iron Triangle Partners LP acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 49,555 shares of the company’s stock, valued at approximately $37,810,000. Eli Lilly and Company accounts for 5.4% of Iron Triangle Partners LP’s investment portfolio, making the stock its 6th biggest position.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Sumitomo Mitsui Financial Group Inc. acquired a new stake in shares of Eli Lilly and Company during the second quarter worth $27,000. Evolution Wealth Management Inc. acquired a new position in Eli Lilly and Company in the 2nd quarter valued at $29,000. Steph & Co. increased its stake in Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares during the period. Financial Gravity Companies Inc. purchased a new position in Eli Lilly and Company during the 2nd quarter worth $31,000. Finally, Bare Financial Services Inc raised its position in Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after buying an additional 29 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Top analysts reiterated bullish ratings and raised targets for LLY, citing continued GLP‑1 growth and the launch of Employer Connect to broaden access to obesity medicines — supporting upside expectations. Wall Street Firms Turn Bullish on Eli Lilly and Company (LLY) Buoyed by GLP-1 Medication Expansion Plans
• Positive Sentiment: Positive topline Phase 3 pediatric results for EBGLYSS (lebrikizumab) showed meaningful skin clearance and itch relief in children 6 months–18 years, supporting potential label expansion and strengthening Lilly’s immunology growth story. Lilly’s EBGLYSS is first selective IL-13 inhibitor with positive Phase 3 pediatric outcomes
• Positive Sentiment: Management is expanding manufacturing and market reach (including plans to invest in China) to support rollout of orforglipron and other GLP‑1 products, which investors view as capacity/readiness positives for future revenue. Eli Lilly (LLY) to Invest $3 Billion in China Over the Next Decade, Reuters Reports
• Neutral Sentiment: A congressional purchase of LLY was disclosed (standard 45‑day lag); such filings can draw attention but are typically not a fresh driver for price moves once public. Members of Congress Bought These 5 Stocks—Should You?
• Negative Sentiment: New rival oral GLP‑1 candidates are posting strong mid‑stage weight‑loss results (Structure Therapeutics and others), raising competitive risk that could pressure Lilly’s market share or pricing over time. Structure Weight-Loss Pill Results Rival Novo, Lilly Treatments
• Negative Sentiment: Investor commentary warns valuation already reflects a lot of GLP‑1 upside, suggesting limited near‑term upside and greater sensitivity to any negative news or weaker growth execution. Is There Too Much Bullishness Priced Into Eli Lilly’s Stock Price?

Wall Street Analyst Weigh In

LLY has been the topic of several analyst reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Guggenheim increased their price target on shares of Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Argus lifted their price objective on Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a report on Monday, February 9th. Finally, HSBC reiterated a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,229.59.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $987.83 on Tuesday. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The company has a market capitalization of $933.32 billion, a P/E ratio of 43.04, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. The firm has a 50-day moving average price of $1,036.20 and a two-hundred day moving average price of $954.12. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.